Nadia Birocco

Summary

Country: Italy

Publications

  1. doi request reprint The effects of Reiki therapy on pain and anxiety in patients attending a day oncology and infusion services unit
    Nadia Birocco
    SC Oncologia Medica, San Giovanni Battista Hospital, Turin, Italy
    Am J Hosp Palliat Care 29:290-4. 2012
  2. pmc Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network
    Maria P Brizzi
    Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Universita di Torino, Azienda Ospedaliera San Luigi, Regione Gonzole, 10, 10043 Orbassano TO, Italy
    BMC Cancer 9:388. 2009

Collaborators

  • Maria P Brizzi
  • Davide Perroni
  • Benedetta Ferretti
  • Libero Ciuffreda
  • Federico Castiglione
  • Luigi Dogliotti
  • Marco Volante
  • Oscar Alabiso
  • Oscar Bertetto
  • Alfredo Berruti
  • Mauro Papotti
  • Enrica Milanesi
  • Anna Ferrero
  • Sebastiano Bombaci

Detail Information

Publications2

  1. doi request reprint The effects of Reiki therapy on pain and anxiety in patients attending a day oncology and infusion services unit
    Nadia Birocco
    SC Oncologia Medica, San Giovanni Battista Hospital, Turin, Italy
    Am J Hosp Palliat Care 29:290-4. 2012
    ..32 (P = .091). Overall, the sessions were felt helpful in improving well-being, relaxation, pain relief, sleep quality and reducing anxiety. Offering Reiki therapy in hospitals could respond to patients' physical and emotional needs...
  2. pmc Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network
    Maria P Brizzi
    Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Universita di Torino, Azienda Ospedaliera San Luigi, Regione Gonzole, 10, 10043 Orbassano TO, Italy
    BMC Cancer 9:388. 2009
    ..A phase II study was designed to test the activity of protracted 5-fluorouracil (5FU) infusion plus long-acting release (LAR) octreotide in patients with neuroendocrine carcinoma...